Mankind Pharma’s Board of Directors convened on July 30, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. Additionally, the board greenlit the issuance of a corporate guarantee amounting to ₹150 crore in favor of Bharat Serums and Vaccines Limited (BSV), a wholly-owned subsidiary, to secure its credit facilities. The meeting commenced at 02:20 p.m. IST and concluded at 03:10 p.m. IST.
Mankind Pharma Board Meeting Highlights
Mankind Pharma Limited announced significant decisions following its Board of Directors meeting held on July 30, 2026. The meeting, which took place between 02:20 p.m. and 03:10 p.m. IST, saw the approval of key financial and strategic items.
Financial Results Approval
The Board considered and approved the unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026. These results, along with the Limited Review Report issued by M/s. S. R. Batliboi & Co. LLP and M/s. Bhagi Bhardwaj Gaur & Co., Chartered Accountants, have been submitted as Annexure-I.
Corporate Guarantee for Subsidiary
In a significant strategic move, the Board approved the issuance of a corporate guarantee for an aggregate amount of ₹150 crore. This guarantee will be in favor of various banks to secure credit facilities availed or proposed to be availed by Bharat Serums and Vaccines Limited (BSV), a wholly-owned subsidiary of Mankind Pharma. The detailed disclosures regarding this guarantee are provided in Annexure-II.
Auditor’s Certificate
Further, a certificate from the Joint Statutory Auditors, in accordance with Regulation 54 of the Listing Regulations for the quarter ended June 30, 2026, has also been enclosed as Annexure-III.
Source: BSE
